Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
1(25.0%)
Phase 1
1(25.0%)
4Total
Phase 2(2)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00851786Phase 2Completed

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

Role: collaborator

NCT00660972Phase 1Completed

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Role: collaborator

NCT00090779Phase 2Terminated

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

Role: collaborator

NCT00929604Not ApplicableCompleted

HIV Viral Load Monitoring in Resource-Poor Settings

Role: collaborator

All 4 trials loaded